|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: HIV/HCV Co-infection - Whose Niche?
Datamonitor, July 2003, Pages: 78
Introduction
The HIV and hepatitis C (HCV) treatment markets are among the fastest growing infectious disease sectors. As co-infection with HIV and HCV is becoming increasingly common, as a result of shared transmission routes, key players are faced with a series of challenges. These include driving compliance rates, overcoming drug interactions, and accessing high risk populations.
Scope
- Key opinion leader insight into treatment strategies for co-infected HIV/HCV patients
- Case studies featuring the leading global players: Roche, GlaxoSmithKline, Boehringer Ingelheim and Gilead
- Key data and detailed epidemiology of HIV and HCV in the seven major markets: the US, Japan, Germany, France, Italy, Spain, and the UK
- Review of current HIV and HCV markets, including key company market share
Report Highlights
HCV is the most prevalent chronic infection within the HIV cohort, infecting over 30% of HIV positive individuals. However, the HIV/HCV co-infected population is primarily comprised of difficult-to-treat patient groups, such as intravenous drug users (IDUs).
HIV/HCV patient potential is limited by poor compliance and low prevalence rates, limiting the incentive for novel product development. However, penetration of the co-infected market will enable companies to leverage their products into the wider HIV or HCV mono-infected populations.
Treatment of HIV/HCV co-infected patients is complicated by drug-drug interactions and the hepatotoxic side effects of certain HIV products. The design and development of a treatment package with proven efficacy in the co-infected population would provide physicians with a convenient treatment strategy.
Reasons to Purchase
- Identification of key co-infected high-risk patient populations will enable companies to design effective targeting strategies
- Evaluation of current treatment practices highlights areas of clinical unmet need and subsequent potential penetration strategies
- Detailed analysis of existing and pipeline products allows identification of opportunities for company collaboration in the co-infection market.
Customers who bought this item also bought
Stakeholder Opinions: HIV/ HBV Co-infection - More Potency, More Policy
Stakeholder Opinions: Urinary Tract Infections - Ciprofloxacin Leads the Way
Stakeholder Opinions: Minimally Invasive Spinal Surgery - Surgeons Await Helping Hand from Manufacturers
Stakeholder Opinions: Cystic Fibrosis
Stakeholder Opinions: HIV - Reaching the Untapped Patient Population
Stakeholder Opinions: Brain Metastases - Turning Prolonged Survival on its Head?
Stakeholder Opinions: Community Acquired Respiratory Tract Infections - Room for Ketek?
Stakeholder Insight: HIV Related Neuropathic Pain - Useful Niche for Peripheral Companies
|
|
|
|
